Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Janssen Biotech gets rights to autoimmune/inflammation compounds from Phenex
04 Aug 2017
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive rights to Phenex Pharmaceuticals AG’s (small-molecule therapeutics for liver disease and autoimmune/inflammatory disorders) compounds targeting the nuclear hormone receptor RORyt to treat chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?